Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
65
resultados
Última actualización
10/03/2026 [07:22:00]
Resultados 50 a 65 de 65
Resumen de: US20260016490A1
The present disclosure relates to a composition for diagnosing cognitive dysfunction in a companion animal using a nasal fluid sample, and to a kit including the same.
Resumen de: AU2024276342A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: US20260014205A1
Compositions and methods are disclosed herein for the treatment of neurocognitive disorders or central nervous system (CNS) disorders such as Alzheimer's disease (AD) and congenital heart diseases such as hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.
Resumen de: US20260016491A1
A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
Resumen de: WO2026012596A1
The invention relates to a method for diagnosis, disease monitoring and/or therapy guidance in a patient suspected of having a neurodegenerative disease of the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis-spectrum (FTD-ALS-spectrum), comprising (a.) providing a sample obtained from said patient, wherein said sample comprises extracellular vesicles, (b.) determining a level of one or more FTD-ALS-spectrum biomarkers in the extracellular vesicles of said sample, (c.) wherein the level of the one or more biomarkers is indicative of whether the patient has (and/or allows to distinguish between) a neurodegenerative disease of the FTD-ALS-spectrum comprising a Tau-proteinopathy or a neurodegenerative disease of the FTD-ALS-spectrum comprising a TAR DNA-binding protein 43 (TPD-43)-proteinopathy. The invention further relates to a kit for carrying out the method of the present invention, methods of treating patients identified using the method of the invention, methods of determining said FTD-ALS-spectrum biomarkers in the extracellular vesicles of said sample, and samples comprising extracellular vesicles and said FTD-ALS-spectrum biomarkers.
Resumen de: WO2026013413A1
The invention relates to in situ methods for detecting the presence of misfolded proteins in samples (e.g. tissue samples). The invention also relates to the use of said methods in the detection of a proteinopathy or an increased risk thereof in a subject and to methods of determining the efficacy of therapeutic interventions.
Resumen de: WO2026015877A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects having, suspected of having, or at risk for developing Alzheimer's disease (AD).
Resumen de: EP4679097A1
Provided is a method capable of easily and accurately estimating a neurodegenerative condition. A method for estimating a brain neurodegenerative condition includes: a measurement step of measuring a blood sample collected from a subject to obtain measured values of a plurality of neurogranin-related peptides; and a use step of calculating a specific value of a ratio using the measured values of the plurality of neurogranin-related peptides, and using the specific value of the ratio to determine a neurodegenerative condition.
Resumen de: EP4679096A1
Provided are a biomarker capable of estimating a neurodegenerative condition by a simple method and an estimation method for the neurodegenerative condition. The biomarker for determining the brain neurodegenerative condition includes at least one selected from the group consisting of Ng53-75, Ng53-78, Ng48-75, Ng44-75 and Ng43-78 in the blood sample.
Resumen de: US2025361504A1
The present disclosure relates, in general, to methods of preparing a spatial proteome and/or transcriptome sequencing library. The spatial proteome and/or transcriptome sequencing library from a biological sample is useful, in some aspects, to determine a genetic profile and help diagnose a subject who has or is at risk of having a disorder, and improve treatment of the subject.
Resumen de: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: ZA202502606B
The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: US20260016490A1
The present disclosure relates to a composition for diagnosing cognitive dysfunction in a companion animal using a nasal fluid sample, and to a kit including the same.
Nº publicación: KR20260005096A 09/01/2026
Solicitante:
UNIV SOOKMYUNG WOMENS IND ACAD COOP FOUND [KR]
DAEGU GYEONGBUK INST SCIENCE & TECH [KR]
UNIV AJOU IND ACADEMIC COOP FOUND [KR]
\uC219\uBA85\uC5EC\uC790\uB300\uD559\uAD50\uC0B0\uD559\uD611\uB825\uB2E8,
\uC7AC\uB2E8\uBC95\uC778\uB300\uAD6C\uACBD\uBD81\uACFC\uD559\uAE30\uC220\uC6D0,
\uC544\uC8FC\uB300\uD559\uAD50\uC0B0\uD559\uD611\uB825\uB2E8
Resumen de: KR20240025073A
The ANKS1A-A355D protein variants are found in Alzheimer's patients, and unlike normal ANKS1A proteins, they fail to efficiently remove toxic proteins such as beta-amyloid peptides because they do not induce the expression of the LRP1 receptor cell membrane. Therefore, the present invention provides a method for providing early diagnosis information on the onset of Alzheimer's disease by confirming the expression level of an ANKS1A-A355D protein variant or detecting whether a gene encoding the ANKS1A-A355D protein variant is retained. In addition, the present invention provides a composition comprising an agent for detecting an ANKS1A-A355D protein variant or a polynucleotide encoding the same.
BOPI
Sede Electrónica
